×
Choose Speciality

EXPLORE!

LOGIN

Combination of Empagliflozin and linagliptin: A Leap Towards Holistic Type 2 Diabetes Management

  955 Views

Dr Binayak Sinha    26 November 2018

  1. The combination addresses multiple pathophysiological defects. The high efficacy provides significant reduction in A1c across baselines. It offers significant weight reduction as well as BP (both systolic and diastolic) reduction.
  2. Empagliflozin provides cardiorenal protection and reduction in CV mortality. Linagliptin has proven CV and renal safety and possible renal benefit.
  3. Absence of any additional safety concerns along with the potential of lower GTIs with FDC vs. SGLT2i alone. The convenience of a single once-daily pill increases patient compliance.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.